Showing 1 - 1 results of 1 for search 'Martin Kaul', query time: 0.02s Refine Results
  1. 1
    Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

    Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial by Martin Kaul, Peter End, Maciej Cabanski, Carole Schuhler, Annamaria Jakab, Magdalena Kistowska, Arvind Kinhikar, Alessio Maiolica, Angela Sinn, Rainard Fuhr, Bruno Cenni

    Published 2021-09-01
    Get full text
    Article

Search Tools: